C. Langford

P. Merkel, L. Moreland, L. Zgaga, 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Pulmonary Eosinophilic Granulomatosis with Polyangiitis has IgG4 Plasma Cells and Immunoregulatory Features.

M. Yandell, P. Merkel, F. Clayton, 2020, The American journal of pathology.

Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

P. Merkel, J. Zwerina, P. Monach, 2015, PloS one.

IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis

P. Merkel, J. Stone, John C. Davis, 2011, Proceedings of the National Academy of Sciences.

Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis

P. Merkel, L. Moreland, P. Monach, 2022, Interactive journal of medical research.

Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments

R. Mustafa, S. Chung, A. Dua, 2021, ACR open rheumatology.

Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America

P. Merkel, L. Moreland, S. Chung, 2021, ACR open rheumatology.

Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.

P. Merkel, K. Maksimowicz-McKinnon, P. Monach, 2015, Rheumatology.

Rituximab for the Treatment of Relapses in ANCA-associated Vasculitis

P. Merkel, J. Stone, L. Viviano, 2014 .

Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, L. Viviano, 2014, Arthritis & rheumatology.

Use of Cytotoxic Agents and Cyclosporine in the Treatment of Autoimmune Disease: Part 2: Inflammatory Bowel Disease, Systemic Vasculitis, and Therapeutic Toxicity

S. James, J. Klippel, J. Balow, 1998, Annals of Internal Medicine.

An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.

P. Merkel, B. Shea, G. Tómasson, 2022, Seminars in arthritis and rheumatism.

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

P. Merkel, M. Weisman, M. Nodale, 2020, Annals of the Rheumatic Diseases.

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

Outcomes of Nonsevere Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated With Glucocorticoids

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

Prevention and Treatment of Medical Complications

A. Khasnis, C. Langford, 2012 .

Update on the Treatment of Granulomatosis with Polyangiitis (Wegener’s)

C. Langford, 2012, Current Treatment Options in Cardiovascular Medicine.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

S. Yancey, P. Merkel, F. Moosig, 2017, The New England journal of medicine.

Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.

S. Yancey, P. Merkel, F. Moosig, 2019, The Journal of allergy and clinical immunology.

Eosinophilia in Rheumatologic/Vascular Disorders.

C. Langford, S. Chatterjee, H. Tamaki, 2015, Immunology and allergy clinics of North America.

Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018 .

Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018, Arthritis & rheumatology.

Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets

P. Merkel, J. Stone, C. Kallenberg, 2016, Arthritis & rheumatology.

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2013, Arthritis and rheumatism.

Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis.

C. Langford, M. Sneller, C. Talar-Williams, 2004, Arthritis and rheumatism.

A 39-Year-Old Postpartum Woman With Foot Drop and Shortness of Breath.

Michael A. Bolen, David O. Taylor, C. Langford, 2016, Chest.

Clinical features and diagnosis of small-vessel vasculitis

C. Langford, 2012, Cleveland Clinic Journal of Medicine.

Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments

R. Mustafa, S. Chung, A. Dua, 2021, ACR open rheumatology.

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis

J. Block, P. Merkel, L. Moreland, 2020, Arthritis care & research.

Sequence‐Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2

P. Merkel, E. Remmers, D. Kastner, 2020, Arthritis & rheumatology.

Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3

P. Merkel, J. Stone, C. Kallenberg, 2019, bioRxiv.

Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018, Rheumatology.

Sinonasal Imaging Findings in Granulomatosis with Polyangiitis (Wegener Granulomatosis): A Systematic Review

R. Sindwani, C. Langford, Brian D’Anza, 2017, American journal of rhinology & allergy.

Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis

C. Langford, C. Langford, 2011, Clinical and experimental immunology.

Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis

C. Langford, E. Molloy, 2008, Nature Clinical Practice Rheumatology.

Does the dose of methotrexate influence the rate of relapse in patients with Wegener's granulomatosis?

C. Langford, E. Molloy, 2007, Nature Clinical Practice Rheumatology.

Can methotrexate replace cyclophosphamide in the treatment of a subset of Wegener's granulomatosis and microscopic polyangiitis?

G. Hoffman, C. Langford, 2006, Nature Clinical Practice Rheumatology.

Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener’s granulomatosis

T. Cox, M. Robinson, C. Langford, 2005, British Journal of Ophthalmology.

Pituitary involvement by Wegener's granulomatosis: a report of two cases.

N. Patronas, C. Langford, M. Sneller, 1999, AJNR. American journal of neuroradiology.

Rituximab With or Without a Conventional Maintenance Agent in the Treatment of Relapsing Granulomatosis With Polyangiitis (Wegener's): A Retrospective Single‐Center Study

G. Hoffman, C. Langford, J. Springer, 2014, Arthritis & rheumatology.

Methotrexate use in systemic vasculitis.

G. Hoffman, C. Langford, M. Sneller, 1997, Rheumatic diseases clinics of North America.

Biologic therapies in the vasculitides.

C. Langford, M. Sneller, 2003, Current opinion in rheumatology.

Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10.

B. Ludviksson, A. Fauci, W. Strober, 1998, Journal of immunology.

Reversal with IL-10 Unbalanced Th1-Type T Cell Cytokine Pattern: T Cells Exhibiting an + CD4 + with HLA-DR Active Wegener's Granulomatosis Is Associated

A. Fauci, W. Strober, C. Langford, 1998 .

Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis.

C. Langford, M. Sneller, C. Talar-Williams, 2000, Arthritis and rheumatism.

The diagnostic utility of c-ANCA in Wegener's granulomatosis.

C. Langford, Carol A. Langford, 1998, Cleveland Clinic journal of medicine.

Management of Wegener's granulomatosis and microscopic polyangiitis

C. Langford, C. Koening, J. Springer, 2010 .

Pregnancy in vasculitis

C. Langford, G. Kerr, 2002, Current opinion in rheumatology.

Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA‐Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2021, ACR open rheumatology.

A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.

C. Langford, M. Sneller, K. Barron, 1999, Arthritis and rheumatism.

Biologic Therapies : Clinical Implications for Rheumatologists , Gastroenterologists , Allied Health Practitioners

C. Langford, E. Husni, 2022 .

Small-vessel vasculitis: Therapeutic management

C. Langford, 2007, Current rheumatology reports.

Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse.

C. Langford, M. Sneller, K. Barron, 2003, The American journal of medicine.

Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

P. Merkel, L. Moreland, P. Monach, 2017, Clinical and experimental rheumatology.

The future of damage assessment in vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2007, The Journal of rheumatology.

A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.

Zonghui Hu, C. Langford, M. Sneller, 2012, Arthritis and rheumatism.

An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)

J. Krischer, P. Merkel, P. Monach, 2013, Annals of the rheumatic diseases.

Granulomatosis With Polyangiitis (Wegener’s)

G. Hoffman, C. Langford, J. Springer, 2014, Medicine.

How can relapses be detected and prevented in primary systemic small-vessel vasculitides?

C. Langford, 2005, Best practice & research. Clinical rheumatology.

Treatment of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: where do we stand?

C. Langford, 2001, Arthritis and rheumatism.

Management of Wegener Granulomatosis

E. White, J. Lynch, H. Tazelaar, 2005 .

Management of systemic vasculitis.

C. Langford, Carol A. Langford, 2001, Best practice & research. Clinical rheumatology.

Wegener's granulomatosis: current and upcoming therapies

C. Langford, 2003, Arthritis research & therapy.

Sinonasal Wegener granulomatosis: A single‐institution experience with 120 cases

Guy Hoffman, M. Citardi, G. Hoffman, 2009, The Laryngoscope.

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes.

D. T. Gray, Janet A. Blood, I. Bruce, 2020, Rheumatology.

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

P. Merkel, J. Stone, Hyon K. Choi, 2015, Annals of the rheumatic diseases.

Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Comment on the Article by Crickx et al

L. Calabrese, R. Hajj-Ali, C. Langford, 2016, Arthritis & rheumatology.

Cardiac Involvement in Granulomatosis with Polyangiitis

P. Merkel, L. Moreland, P. Monach, 2015, The Journal of Rheumatology.

Upper airway obstruction in the rheumatic diseases.

C. Van Waes, C. Waes, C. Langford, 1997, Rheumatic diseases clinics of North America.

Kawasaki Disease: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments

R. Mustafa, S. Chung, A. Dua, 2021, ACR open rheumatology.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2010, The New England journal of medicine.

KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis.

H. Trachtman, L. Mariani, A. Bomback, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

J. Krischer, P. Merkel, J. Stone, 2011, Arthritis and rheumatism.

Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis.

P. Merkel, L. Moreland, Marcus Y. Chen, 2019, Rheumatology.

Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3

D. Schroeder, P. Merkel, J. Stone, 2016, Arthritis & rheumatology.

A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.

P. Gregersen, C. Wijmenga, J. Barrett, 2015, American journal of human genetics.

Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis

P. Merkel, K. Maksimowicz-McKinnon, P. Monach, 2013, Journal of Rheumatology.

Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis

J. Krischer, P. Merkel, J. Stone, 2011, Annals of the rheumatic diseases.

A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.

C. Wijmenga, J. Barrett, B. Lie, 2017, American journal of human genetics.

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis

Naoto Hirano, Christopher I. Amos, Xuemei Ji, 2017, Arthritis & rheumatology.

Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis

P. Merkel, J. Stone, C. Kallenberg, 2020, JCI insight.

Identification of multiple genetic susceptibility loci in Takayasu arteritis.

P. Merkel, J. Guthridge, O. Karadag, 2013, American journal of human genetics.

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

Methotrexate as an alternative to classic immunosuppressive therapies

G. Hoffman, C. Langford, 2001 .

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2018, Clinical journal of the American Society of Nephrology : CJASN.

Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis.

Stephan Ripke, Delnaz Roshandel, Soumya Raychaudhuri, 2013, Arthritis and rheumatism.

Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis

P. Merkel, K. Maksimowicz-McKinnon, P. Monach, 2012, Annals of the rheumatic diseases.

A 72-year-old man with a purpuric rash

C. Langford, S. Goel, 2009, Cleveland Clinic journal of medicine.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.

P. Merkel, J. Stone, C. Kallenberg, 2015, Journal of the American Society of Nephrology : JASN.

Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis : Which Subsets Are At Greatest Risk for Flare?

P. Merkel, J. Stone, C. Kallenberg, 2011 .

Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

P. Merkel, Javier Martín, M. González-Gay, 2017, Scientific Reports.

Update on vasculitis.

A. Khasnis, C. Langford, 2009, The Journal of allergy and clinical immunology.

Substitution of Methotrexate for Cyclophosphamide in Wegener Granulomatosis: A 12-Year Single-Practice Experience

E. Mascha, M. Karafa, G. Hoffman, 2007, Medicine.

Tarsal-conjunctival disease associated with Wegener's granulomatosis.

T. Cox, M. Robinson, Janine A. Smith, 2003, Ophthalmology.

Inflammatory Diseases of Blood Vessels: Hoffman/Inflammatory Diseases of Blood Vessels

G. Hoffman, C. Weyand, J. Goronzy, 2012 .

Update on the diagnosis and treatment of Wegener's granulomatosis.

C. Langford, M. Sneller, 2001, Advances in internal medicine.

Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou et al.

G. Hoffman, C. Langford, 2013, Arthritis and rheumatism.

Orbital involvement in Wegener granulomatosis: MR findings in 12 patients.

N. Patronas, C. Langford, M. Sneller, 1997, Journal of computer assisted tomography.

Treatment of ANCA-associated vasculitis.

C. Langford, 2003, The New England journal of medicine.

Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review of randomized trials.

P. Merkel, R. Christensen, G. Tómasson, 2020, Seminars in arthritis and rheumatism.

Pilot study to assess the frequency of fibromyalgia, depression, and sleep disorders in patients with granulomatosis with polyangiitis (Wegener's)

J. Bena, G. Hoffman, L. Calabrese, 2011, Arthritis care & research.

The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.

D. Schroeder, P. Merkel, J. Stone, 2019, Journal of autoimmunity.

Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis

P. Merkel, J. Stone, C. Kallenberg, 2017, American Journal of Nephrology.

The interface of inflammation and subclinical atherosclerosis in granulomatosis with polyangiitis (Wegener's): a preliminary study.

J. Major, R. Silverstein, G. Hoffman, 2015, Translational research : the journal of laboratory and clinical medicine.

Update on Wegener granulomatosis.

C. Langford, 2005, Cleveland Clinic journal of medicine.

Efficacy of leflunomide in the treatment of vasculitis.

P. Merkel, L. Moreland, L. Barra, 2020, Clinical and experimental rheumatology.

Polypoid lesions of airways: early experience with computer-assisted detection by using virtual bronchoscopy and surface curvature.

J D Malley, R M Summers, J. Shelhamer, 1998, Radiology.

Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2017, Arthritis care & research.

Use of 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu's Arteritis.

P. Merkel, M. Ahlman, C. Langford, 2022, Rheumatology.

The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

B. Rovin, P. Merkel, J. Stone, 2016, Arthritis & rheumatology.

Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2020, Frontiers in Immunology.

Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments

R. Mustafa, S. Chung, A. Dua, 2021, ACR open rheumatology.

New insights into the immunopathogenesis and treatment of small vessel vasculitis of the kidney

J. Balow, C. Langford, 2003, Current opinion in nephrology and hypertension.

SAT0012 DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS

P. Merkel, J. Stone, J. Pers, 2019, SATURDAY, 15 JUNE 2019.

Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma.

P. Merkel, L. Moreland, P. Nair, 2019, Clinical and experimental rheumatology.

Chronic immunosuppressive therapy for systemic vasculitis.

C. Langford, 1997, Current opinion in rheumatology.

Inflammatory disease of the aorta: patterns and classification of giant cell aortitis, Takayasu arteritis, and nonsyndromic aortitis.

B. Lytle, L. Svensson, E. Blackstone, 2015, The Journal of thoracic and cardiovascular surgery.

Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2021, JCI insight.

Safety of Trimethoprim-Sulfamethoxazole for Pneumocystis Jirovecii Pneumonia Prophylaxis in Patients Taking Methotrexate.

J. Parambil, C. Langford, Alexander Chaitoff, 2020, Journal of the American Academy of Dermatology.

Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis

P. Merkel, J. Stone, L. Leng, 2018, Arthritis & rheumatology.

J. Krischer, P. Merkel, C. Langford, 2017, Arthritis & rheumatology.

Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis

J. Farrar, P. Merkel, L. Moreland, 2019, The Journal of Rheumatology.

083. COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU’S ARTERITIS AND GIANT CELL ARTERITIS

P. Merkel, L. Moreland, K. Maksimowicz-McKinnon, 2019, Rheumatology.

Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

P. Merkel, Javier Martín, M. González-Gay, 2017, Scientific Reports.

THU0301 Safety following initiation of rituximab in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA): interim analysis of the rituximab in anca-associated vasculitis registry (RAVER)

D. Wallace, P. Monach, P. Duncombe, 2017 .

053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS

D. Schroeder, P. Merkel, J. Stone, 2019, Rheumatology.

Improved virtual bronchoscopy using a multislice helical CT scanner

Ronald M. Summers, Bradford J. Wood, Michael C. Sneller, 2000, Medical Imaging.

Implications of antineutrophil cytoplasmic antibody status when switching to maintenance therapy.

J. Stone, G. Hoffman, C. Langford, 2005, Arthritis and rheumatism.

Finding a valid model for human Wegener's granulomatosis: comment on the article by Tomer et al.

C. Langford, M. Sneller, 1996, Arthritis and rheumatism.

Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis.

K. Siminovitch, S. Raychaudhuri, C. Amos, 2013, Arthritis and rheumatism.

Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020.

P. Tugwell, B. Shea, G. Tómasson, 2021, Seminars in arthritis and rheumatism.

Damage in ANCA-associated vasculitis: Preliminary evidence for the ANCA-associated vasculitis index of damage (AVID).

J. Stone, C. Kallenberg, E. Clair, 2006 .

Update on vasculitis.

A. Khasnis, C. Langford, 2009, The Journal of allergy and clinical immunology.

New insights into the immunopathogenesis and treatment of small vessel vasculitis of the kidney

J. Balow, C. Langford, 2003, Current opinion in nephrology and hypertension.